Tag Archive for: clinical study

Tulyp Medical emerges from Sofinnova’s medtech accelerator and announces FDA submission following initial first-in-human use

/in

Company unveils patented technology designed to help maintain healthy blood flow during vascular procedures Backed by Sofinnova MD Start and led by experienced medtech entrepreneurs and cardiologists PARIS, France – November 4, 2025 – Tulyp Medical, a Paris-based startup developing a medical device  for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted […]

Read more

Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025

/in

EMERALD Chief Investigator Prof. Jonathan Fallowfield will present the poster on study design EMERALD is a multicentre Phase I/II study evaluating Resolution’s Regenerative Macrophage Therapy RTX001 in patients with end-stage liver disease taking place in the UK and Spain First patient dosed successfully, and safety cleared at Royal Infirmary of Edinburgh Edinburgh and London, UK, […]

Read more

Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial

/in

Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency rates, with major improvements demonstrated across the board compared to standard of care Enhances clinical profile of aXess, reinforcing excellent first-in-human outcomes amid ongoing US pivotal trial and ahead of commercialization EINDHOVEN, The Netherlands, 24 […]

Read more

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

/in

Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth in inflammatory and fibrotic indications beyond liver disease Paul Sekhri, seasoned life sciences executive with decades of drug development and […]

Read more

Invizius receives MHRA approval to commence First-in-Human clinical study of H-Guard® Priming Solution

/in

Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence its First-in-Human clinical study of lead product, H-Guard. The study will be conducted at the […]

Read more